ALLERGY THER. PLC LS-001
Research ALLERGY THER. PLC LS-001 (HHU) on Bullrun: market cap EUR 345.09M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHHU
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 345.09M
- Financial periodFY2025
- RevenueGBP 55.04M
- Revenue growth-0.3%
- Net income-GBP 40.13M
- Free cash flow-GBP 31.53M
- Gross margin53.2%
Valuation Snapshot
latest market cap is EUR 345.09M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 55.04M | -GBP 40.13M | -GBP 31.53M | 53.2% | -0.01 | GBP 12.59M | GBP 60.09M | -GBP 28.19M |
| FY2024 | GBP 55.20M | -GBP 38.62M | -GBP 35.54M | 53.9% | -0.01 | GBP 12.72M | GBP 30.99M | GBP 7.36M |
| FY2023 | GBP 59.59M | -GBP 43.07M | -GBP 33.55M | 55.8% | -0.08 | GBP 14.65M | GBP 35.99M | GBP 4.11M |
| FY2022 | GBP 72.77M | -GBP 13.78M | -GBP 17.06M | 68.0% | -0.02 | GBP 20.32M | GBP 10.53M | GBP 37.77M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 345.09M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ALLERGY THER. PLC LS-001
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ALLERGY THER. PLC LS-001's market cap?
ALLERGY THER. PLC LS-001's market capitalization is EUR 345.09M.
What does ALLERGY THER. PLC LS-001 do?
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus.